EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

ABSTRACT:

Purpose

The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab.

Methods

We performed a retrospective review of patients with a diagnosis of glioblastoma who were treated with bevacizumab in the recurrent setting at our hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-oncologists, based on clinical and radiographi

SUBMITTER: Hovinga KE 

PROVIDER: S-EPMC6752204 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature